Affilogic is a biotech company that was established in Nantes in 2010. They specialize in the development and combination of Nanofitins®, which are alternative scaffolds that mimic antibodies. With their innovative technology and strong intellectual property portfolio, Affilogic has exclusive worldwide rights to this technology and can generate custom Nanofitins® with high binding affinity and controlled specificity for various purposes, including detection, capture, targeting, and interaction.

They have a proprietary discovery process and work closely with their partners to develop Nanofitins® against specific targets. Affilogic is an independent private company and has achieved significant success through international collaborations with pharma and biotech companies. They also have strong ties to the local community and are a major member of the Atlanpole Biotherapies cluster in Nantes.

With their recent move to larger facilities equipped for Nanofitin® discovery and non-GMP production, Affilogic is well-positioned to continue their cutting-edge research in therapeutic applications